122 related articles for article (PubMed ID: 36372140)
21. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
22. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
23. [Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan Z; Zhang Y; Huang F; Dai M; Li Y; Nie D; Lin D; Jiang Q; Sun J; Xiao Y; Liu Q
Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(24):1915-20. PubMed ID: 26710693
[TBL] [Abstract][Full Text] [Related]
24. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
25. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy analysis of unrelated donor hematopoietic stem cell transplantation for treatment of high risk acute myeloid leukemia].
Ye F; Tang XW; Sun AN; Qiu HY; Jin ZM; Fu ZZ; Chen F; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):696-701. PubMed ID: 23815925
[TBL] [Abstract][Full Text] [Related]
27. Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children.
Schechter T; Avila L; Frangoul H; Domm J; Dupuis LL; Naithani R; Zhao X; Pollock-Barziv S; Roifman C; Gassas A; Doyle J
Leuk Lymphoma; 2013 Jan; 54(1):105-9. PubMed ID: 22721498
[TBL] [Abstract][Full Text] [Related]
28. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
30. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.
Fowler KA; Li K; Whitehurst CB; Bruce DW; Moorman NJ; Aubé J; Coghill JM
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1062-1074. PubMed ID: 30668984
[TBL] [Abstract][Full Text] [Related]
31. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
32. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
[TBL] [Abstract][Full Text] [Related]
33. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
34. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF
Leuk Res; 2017 Aug; 59():1-7. PubMed ID: 28527401
[TBL] [Abstract][Full Text] [Related]
36. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
37. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.
Kröger N; Shahnaz Syed Abd Kadir S; Zabelina T; Badbaran A; Christopeit M; Ayuk F; Wolschke C
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2152-2156. PubMed ID: 29800615
[TBL] [Abstract][Full Text] [Related]
38. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.
Delia M; Carluccio P; Mestice A; Chiusolo P; Metafuni E; Bellesi S; Arpinati M; Milone GA; Martino M; Mazza P; Ingrosso C; Vacca A; Saporiti G; Zallio F; Attolico I; Pastore D; Specchia G; Albano F; Musto P
Transplant Cell Ther; 2021 Nov; 27(11):918.e1-918.e9. PubMed ID: 34403789
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]